Objective: Increased secretion of atrial and brain natriuretic peptide (ANP and BNP) from hearts is known to exhibit favorable effects in patients and animals with heart failure, and inhibition of neutral endopeptidase (NEP), an enzyme that degrades ANP and BNP, may further increase these peptide levels. However, it is still unknown whether such elevation of the ANP and BNP may offer a therapeutic benefit to the progression of chronic heart failure (CHF). We examined the effects of ONO-9902, a novel NEP inhibitor, on changes in hemodynamic parameters, NEP activity and neurohumoral factors in rats with CHF induced by left coronary artery ligation (CAL). Methods: Male Wistar rats (220-240 g) were subjected to induction of acute myocardial infarction by CAL. Rats were orally treated with ONO-9902 (300 mg / kg / day) from the 1st to 6th week after the operation. Hemodynamic and / or biochemical assessments were performed at the 1st and 6th weeks after the operation. Results: A single administration of ONO-9902 inhibited the plasma and kidney NEP activities and thereby further augmented the elevation of plasma ANP concentration in rats with CAL at the 1st week after the operation. In rats with CAL at the 6th week after the operation, the left ventricular end-diastolic pressure (LVEDP) increased and cardiac output index (COI) decreased as compared with those of sham-operated rats. These changes were accompanied by marked increases in the plasma ANP, BNP and endothelin-1 (ET-1). Chronic treatment with ONO-9902 attenuated the increase in LVEDP and the decrease in COI. These changes were associated with a decrease in plasma ANP, BNP and ET-1 concentrations. Conclusions: The results suggest that chronic treatment with NEP inhibitor improves depressed cardiac function in rats with CHF. ONO-9902 may offer a new and possible therapeutic approach in patients with CHF.
Introduction
cardiac output in patients with congestive heart failure whose plasma concentrations of ANP and BNP had It is well established that circulating levels of atrial and already been high as compared with those of normal brain natriuretic peptide (ANP and BNP) are elevated in subjects [4] [5] [6] . These findings imply that only a high level patients with chronic heart failure (CHF) in proportion to of endogenous ANP and BNP would not improve the the severity of the disease [1, 2] . Unlike vasoconstrictor pathophysiology of heart failure and that an additional peptides such as angiotensin II and endothelin-1 (ET-1), increase in these peptides may be necessary to elicit the ANP and BNP have been shown to exhibit beneficial improvement. However, the therapeutic potential of ANP effects on systemic circulation in patients with CHF and BNP themselves is limited because these peptides are including dilatation of resistance vessels, natriuresis and inactive in an oral administration and are short-acting after diuresis [3] . It has been reported that infusion of ANP or intravenous administration. Thus, an orally active analogue BNP decreased both preload and afterload and increased of drugs that can inhibit their degradation would be expected to be useful for the therapy of CHF. Neutral endopeptidase (NEP; also called enkephalinase, CALLA / CD10, EC3.4.24.11) is a zinc-containing memIt is anticipated that chronic treatment with a NEP brane-bound enzyme that is widely distributed in organs, inhibitor, like acute treatment with a NEP inhibitor as particularly in the kidney [7] and lungs [8] with a high described above [14] , may increase plasma levels of ANP activity. NEP degrades ANP by cleaving the Cys7-Phe8
and BNP due to an inhibition of their degradation enzyme. bond of the peptide [9] . Since NEP plays a major role in Conversely, if the sustained elevation of circulating levels the clearance of ANP under pathological conditions where of these peptides is beneficial to CHF, long-term treatment there is a higher plasma concentration as in CHF [10] , with the NEP inhibitor may reduce the plasma ANP and NEP inhibition is regarded as a process of maintaining the BNP levels rather than elevate their levels as a result of the biological activity of endogenous ANP by preventing its improvement of the pathophysiology of CHF. Thus, we degradation. Therefore, inhibition of the ANP degradation also examined both acute and chronic effects of NEP by treatment with NEP inhibitor would be expected to inhibitor treatment on the plasma ANP and BNP conexert beneficial effects on CHF because of amplification of centrations in rats with CHF. the ANP action. Indeed, acute treatment with NEP inIn this study, we used ONO-9902, as a novel NEP hibitors has been shown to produce therapeutically favorinhibitor, which was recognized as an anti-nociceptive able responses, including reduction in systemic blood agent due to its ability to inhibit enkephalinase [17] . pressure [11] , increases in cardiac output [12] and renal However, its effect on cardiovascular function in CHF has natriuretic action [13] and a decrease in the right atrial and not been clarified. This drug is an oral prodrug, which is pulmonary capillary wedge pressure [14] in various exhydrolyzed to release the active form, ONO-BB-039-02. perimental models of heart failure or in patients with CHF.
The chemical structures of these compounds are shown in In contrast to the beneficial acute effects, treatment with Fig. 1 . candoxatril, a NEP inhibitor that is orally active prodrug of candoxatrilat, for 10 days failed to produce favorable hemodynamic effects in patients with CHF [15] . In addi-2. Methods tion, treatment with candoxatril for 4 weeks in the animal models of CHF failed to oppose cardiac hypertrophy [16] .
2.1. Animals There are, as far as we know, no reports concerning the benefit of long-term treatment with a NEP inhibitor for Male Wistar rats weighing 220-240 g (SLC, CHF. The present study was undertaken to examine Hamamatsu, Japan) were used in the present study. The whether long-term treatment with NEP inhibitor may animals were fed with standard rat chow and tap water ad produce beneficial effects in rats with CHF following left libitum, maintained at 23618C with a constant humidity of coronary artery ligation (CAL).
5565%, and acclimated with a cycle of 12 h of light and 12 h of darkness. All experiments were performed according to the Guidelines of Experimental Animal Care issued by Prime Minister's Office of Japan, which is essentially in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) . The protocol of the study was approved by the Animal Care Committee of the Tokyo University of Pharmacy and Life Science.
Heart failure following left coronary artery ligation
Myocardial infarction was produced by CAL according to the method described previously [18] . Briefly, the animals were anaesthetized with pentobarbital sodium (45 mg / kg, i.p.), intubated and artificially ventilated with air. The p , p and pH values of the animal under surgery,
when determined in a preliminary study, were 97.465.7 mmHg, 40.061.1 mmHg and 7.4460.02 (n56), respectively. The skin was incised along the left sternal border, and the fourth rib was cut proximal to the sternum. The pericardial sac was perforated, and the heart was exteriorized through the intercostal space. The left coronary artery was ligated approximately 2 mm from its origin with a monitored. The animals that showed a large Q wave (.1 mV) were considered to have developed acute myocardial infarction and were used for the following experiments. Among 124 animals that had undergone the operation, 35 died within 24 h and 9 within 1 week of the operation. The 80 remaining rats were used for the following studies. Sixty-four sham-operated (Sham) rats without CAL were treated similarly. Using these animals, we assessed acute and chronic effects of the NEP inhibitor. Experimental protocols and numbers of animals used for various series of experiments are shown in Fig. 2 and Table 1 , respectively.
Treatment with ONO-9902
To assess the effects of acute treatment with ONO-9902, we orally treated the rats with a single dose of 300 mg / kg body weight of ONO-9902 7 days after CAL or sham operation. For evaluation of the effects of long-term treatment with ONO-9902, both rats with CAL and Sham rats were orally treated with 300 mg / kg body weight of ONO-9902 once daily for 5 weeks from the 1st to the 6th week after the operation. The drug solution in a volume of 1 ml / 200 g body weight was administered into the stomach through a probe. The dose used in the present study was based on the in vivo anti-nociceptive effect of To assess the effects of ONO-9902, we determined NEP on rats with CAL or Sham rats at the 6th week after the operation were examined. Rats with CAL and Sham rats were treated with 300 mg / kg / activities in plasma, kidney and lungs at 24 h after the oral body weight of ONO-9902 once daily from the 1st to 6th week after the administration of ONO-9902 to rats with CAL and Sham operation. The morphology, hemodynamics and biochemical markers rats. Under anesthesia with diethylether, blood was colwere determined 6 weeks after the operation. lected via the abdominal aorta, and the kidney and lungs suture of 5-0 silk string. The heart was repositioned in the were dissected. For determination of NEP activity, we chest and the wound was then sutured with strings. At 24 h employed HPLC-linked fluorimetric method using sucafter the operation, the rats were lightly anaesthetized with cinyl-Ala-Ala-Phe-aminomethylcoumarine (AMC) diethylether and their electrocardiograms (lead I) were (Sigma, St. Louis, MO, USA) as a synthetic substrate for Table 6 a Fifty rats at the 1st week after the operation were used for the acute study and 84 rats at the 6th week after the operation were used for the chronic study.
NEP and thiorphan (Sigma) as a NEP inhibitor. The according to the method described previously [18] . Six principle of this method is similar to that described weeks after the operation, the animals were anesthetized elsewhere [12, 19] . To eliminate non-specific cleavage of with nitrous oxide-oxygen (3:1) and 2.5% halothane. the substrate, thiorphan at a concentration of 1 mM was Anesthesia was continued with a gas mixture of nitrous added to the control tube. The AMC released was sepaoxide-oxygen (3:1) containing 0.5% halothane at the flowrated by reversed-phase HPLC from its substrate and rate of 1.2 l / min through a mask loosely placed on the intermediate products, and the fluorometric intensity was nose. The animals were warmed by an electronic panel determined. NEP activity was calculated from the differheater to maintain their rectal temperature at 36-378C. In a ence in AMC levels between the sample and control.
preliminary study, we analyzed the blood gas of the animal following the operation under the experimental conditions.
Measurement of plasma and tissue ANP, BNP and
The p , p and pH were 101.564.9 mmHg, 40.161.4
ET-1 mmHg and 7.4560.02 (n55), respectively. A microtip pressure transducer (model SPG 320, Miller Instrument, To evaluate the acute effect of ONO-9902 on plasma Houston, TX, USA) was introduced into the ventricle concentrations of ANP and BNP, we used the rats with through the right carotid artery to measure the respective CAL and Sham rats at 1 week after the operation. For LVSP and its dP/dt max by a pressure transducer (model assessment of the chronic effect of ONO-9902 on plasma AB-621-G, Nihonkohden, Tokyo, Japan) and a differenconcentrations of ANP, BNP and ET-1, the rats with CAL tiator (model RD-601G, Nihonkohden). The MAP was and Sham rats, both with and without ONO-9902 treatment measured by means of another pressure transducer (model for 5 weeks, were used. At 24 h after the administration of DX-360, Nihonkohden) connected to a cannula placed into ONO-9902, the plasma was sampled under anesthesia with the right femoral artery. Measurement of HR was triggered diethylether from the abdominal aorta into a chilled tube from changes in MAP (model AT-601G, Nihonkohden). containing aprotinin (300 kallikrein-inhibitable U / ml) and After equilibration for 10 min, the parameters were potassium EDTA (1.5 mg / ml blood). Plasma was separecorded on a thermal pen recorder (model RTA-1200, rated by centrifugation at 2000 g for 10 min at 48C and Nihonkohden). stored at 2808C until assayed. The heart was subsequently
In another set of experiments, aortic blood flow (AF) removed and rinsed in ice-cold normal saline. The scar was measured and the cardiac output index (COI) was area was removed from the left ventricle. The remaining determined by the method described previously [18] . Six left ventricle including the septum was sectioned from the weeks after the operation, the Sham and CAL animals with heart, rapidly frozen in liquid nitrogen and stored at or without ONO-9902 treatment were anesthetized with 2808C. ANP, BNP and ET-1 were extracted from the nitrous oxide-oxygen (3:1) and 2.5% halothane. Then plasma by use of Sep-Pak C cartridges (Waters of each rat was intubated and artificially respirated with a gas 18 Millipore, Milford, MA, USA) that had been preconmixture of nitrous oxide-oxygen (3:1) containing 0.5% ditioned with methanol followed by 0.2 M sodium phoshalothane at the flow-rate of 3.260.3 ml / cycle (60 cycles / phate-citric acid, pH 7.0. Plasma samples were passed min). After thoracotomy, an electromagnetic flow meter through the equilibrated cartridge. After washing with with a diameter of 2-2.5 mm (model MFV-3100, Nihonwater, the cartridges were eluted with methanol-water kohden) was placed around the ascending thoracic aorta (90:10, v / v). To determine the tissue ANP content, we and the AF was then measured. During the measurement of ground the frozen non-infarcted part of the left ventricle to AF, MAP was monitored through a cannula inserted into a fine powder with a mortar and pestle under liquid the femoral artery, and HR was measured via the arterial nitrogen cooling. The powder was homogenized in 1 M pressure recording in a manner similar to that described acetic acid containing 10 ml / ml pepstatin and immediately above. COI was calculated by dividing AF by body boiled for 10 min. After boiling and then chilling, the weight. In a preliminary study, we performed blood gas homogenate was centrifuged at 20 000 g for 30 min at 48C, analysis on the experimental animals and found that the and the supernatant fluid was stored at 2808C until used.
p , p and pH were 98.563.3 mmHg, 37.561.6 mmHg
ANP, BNP and ET-1 concentrations in the supernatant and 7.3860.03 (n55), respectively. fluid were determined by the sandwich-enzyme immunoassay method (Peninsula Lab., San Carlos, CA, USA).
Measurements of myocardial infarct size 2.6. Measurements of hemodynamic parameters
After measurements of hemodynamic parameters, 50 In the first set of experiments, heart rate (HR), mean mM KCl solution was intravenously injected. The heart arterial pressure (MAP), left ventricular systolic pressure was isolated and sectioned into seven slices (1 mm thick) (LVSP), left ventricular end-diastolic pressure (LVEDP), from the base to the apex of the heart in a plane parallel to 1dP/dt max and 2dP/dt max of Sham and CAL animals the atrioventricular groove. The slices were stained at 378C with or without ONO-9902 treatment were measured for 5 min with 1% 2,3,5-triphenyltetrazolium chloride in physiological saline. The infarct areas were determined shown in Fig. 3a and b , respectively. The plasma ANP according to the planimetric method. The estimation was level significantly increased in rats with CAL at the 1st based on determination of the epi-and endo-circumference week after the operation (106.2614.7 vs. 34.065.4 pg / ml of the infarcted myocardium as reported previously [20] .
for Sham rats). This increase in the plasma ANP level was Six weeks after the operation, ten rats that had an infarct further enhanced by treatment with ONO-9902. Treatment size of ,35% of the left ventricle (six drug-treated and with ONO-9902 tended to increase the plasma BNP in rats four untreated animals) were eliminated from the study.
with CAL.
Substances 3.2. Effects of long-term treatment with ONO-9902 on changes in hemodynamic parameters
propionylamino]-4-(NEffects of long-term treatment with ONO-9902 on phenylcarbamoyl)-butyric acid (Fig. 1) was kindly prochanges in body and organ weights in rats with CAL and vided by Ono Pharmaceutical Co. Ltd. (Osaka, Japan).
in Sham rats are shown in Table 3 . Two-way ANOVA showed that the body weight was decreased whereas the 2.9. Statistical analysis lung weight, lung weight / body weight, right ventricular (RV) weight and RV weight / body weight were increased Data are expressed as means6S.E.M. Statistical signifiby CAL. The findings suggest that the rats with CAL cance was estimated by two-way factorial ANOVA folexhibited pulmonary edema and right ventricular hyperlowed by Fisher's PLSD method. Differences with a trophy. Chronic treatment with ONO-9902 significantly probability of ,5% were considered significant (P,0.05).
attenuated the increases in lung weight and lung weight / body weight, whereas it did not affect the increase in heart weight of the rats with CAL. Myocardial infarct size in rats 3. Results with CAL was not affected by the drug treatment (4462 vs. 4563% for untreated CAL group).
Effects of acute treatment with ONO-9902 on NEP
To determine whether the chronic inhibition of NEP activity and on plasma concentrations of ANP and BNP may improve hemodynamic parameters, we examined the effects of long-term treatment with ONO-9902 on changes To examine the degree of inhibitory potency of ONOin HR, MAP, LVSP, LVEDP, 1dP/dt max and 2dP/ dt 9902 on the NEP activity, we measured plasma and tissue max in rats with CAL and Sham rats (Table 4) . Two-way NEP activities of rats with CAL and Sham rats following a ANOVA revealed that an increase in LVEDP of the CAL single administration with ONO-9902 ( Table 2 ). The rats was significantly attenuated by long-term treatment plasma and renal NEP activities of rats with CAL were with ONO-9902. Neither CAL nor treatment with ONOsignificantly reduced, and the pulmonary NEP activity 9902 affected HR or MAP. The decreases in 1dP/dt max tended to be decreased, on treatment with ONO-9902. In and 2dP/dt max tended to be restored by treatment with Sham rats, ONO-9902 significantly decreased plasma, ONO-9902. renal and pulmonary NEP activities. These results indiTo determine whether the chronic inhibition of NEP cated that ONO-9902 inhibited the NEP activity under ex may improve cardiac function, we assessed the effects of vivo conditions irrespective of the presence or absence of long-term treatment with ONO-9902 on changes in AF, CAL. Effects of acute treatment with ONO-9902 on COI, stroke volume index (SVI) and systemic vascular changes in plasma ANP and BNP concentrations are resistance (SVR) in rats with CAL and Sham rats in The animals were treated with a single dose of 300 mg / kg ONO-9902, and 24 h after the administration plasma and tissue samples were taken. NEP activity was determined by HPLC with an aid of synthetic peptide as described in Methods. Each value represents the mean6S.E.M. of 4-7 experiments. Two-way factorial ANOVA was used to determine whether plasma and tissue NEP activities were affected by CAL or treatment with ONO-9902. Differences in mean values for plasma and tissue NEP activities between ONO-9902 treated and untreated groups were tested by post-hoc comparison with Fisher's PLSD method. NEP activity is expressed as the rate of 7-amino-4-methylcoumarin cleavage. NS, no significance.
were restored almost to sham levels and the decrease in AF tended to be restored by chronic treatment with ONO-9902. This drug had no significant effects on these hemodynamic variables of the Sham rats.
Effects of long-term treatment with ONO-9902 on changes in the plasma and left ventricular ANP, BNP and ET-1
Effects of long-term treatment with ONO-9902 on changes in the plasma ANP and BNP concentrations of rats with CAL and of Sham rats are shown in Fig. 4a and b, respectively. The plasma ANP and BNP concentrations were significantly increased in rats with CAL as compared with those of the Sham rats (two-way ANOVA). Longterm treatment with ONO-9902 significantly attenuated the increases in the plasma ANP concentration (176614 to 12463 pg / ml, P,0.0001, post-hoc test) and BNP concentration (8164 to 5363 pg / ml, P,0.0001, post-hoc test). Similarly, the LV ANP content was significantly increased by CAL. Long-term treatment with ONO-9902 prevented the increase in the LV ANP content (Table 6) .
To determine whether long-term treatment with the NEP inhibitor might have affected the plasma ET-1 level and LV ET-1 content, we determined the effects of chronic treatment with ONO-9902 on changes in these parameters in rats with CAL and in Sham rats at the 6th week after the operation (Fig. 5) . The plasma and LV ET-1 levels were significantly increased by CAL (two-way ANOVA). Chronic treatment with ONO-9902 significantly attenuated the increase in both levels. CAL. This is consistent with the effects of the NEP CAL. inhibitor ecadotril (sinorphan), a NEP inhibitor that is an orally active prodrug of (S)-thiorphan, on the plasma NEP another set of experiments (Table 5 ). Baseline hemoactivity and the ANP concentration in rats with heart dynamic parameters of the animals under this experimental failure produced by aortovenocaval (AV) fistula as reported condition was similar to those observed in the first set of by other investigators [19] . In the Sham rats in vivo the experiments except that MAP was slightly lower due to treatment with ONO-9902 also diminished the plasma and thoracotomy. AF, COI and SVI were significantly detissue NEP activities but the plasma concentrations of ANP creased in rats with CAL as compared with those of Sham and BNP were not increased. It is considered that the rats, indicating that CHF with low cardiac output had inactivation of circulating ANP and BNP is attributed to already developed by 6 weeks after CAL. In addition, SVR clearance receptor-mediated internalization and / or enwas significantly increased by CAL. These changes are zymatic degradation of these peptides and that NEP plays a similar to previous data in the rats with CHF at the 8th or major role in the clearance of ANP when its plasma 12th week after CAL reported from our laboratory [18] .
Discussion
concentration of the animals with heart failure is high [10] . The decreases in COI and SVI, and the increase in SVR Therefore, it is conceivable that NEP inhibitors may a Each value represents the mean6S.E.M. of 6-8 experiments. Two-way factorial ANOVA was used to determine whether body and organ weights were affected by CAL or treatment with ONO-9902. Differences in mean values for body and organ weights between ONO-9902 treated and untreated groups were tested by post-hoc comparison with Fisher's PLSD method. Abbreviations: LV, left ventricular; RV, right ventricular; NS, no significance. Table 4 Effects of long-term treatment with ONO-9902 on changes in heart rate (HR), mean arterial pressure (MAP), left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP), 1dP/dt max and 2dP/dt max in rats with left coronary artery ligation (CAL) and in sham-operated rats enhance the biological activity of endogenous ANP and not increased by the acute treatment with ONO-9902, thereby produce the favorable effect only when the plasma whereas plasma ANP was. A similar result was reported in ANP level is high.
the case of acute treatment with ecadotril, a NEP inhibitor, Like plasma ANP, plasma BNP is recognized as a in rats with heart failure induced by AV fistula [19] . One sensitive marker for the degree of severity of CHF [21] . possibility for the difference in response to CHF is that the Our results showed that plasma BNP in CAL animals was affinity of BNP to NEP may be less than that of ANP. In Table 5 Effects of long-term treatment with ONO-9902 on changes in heart rate (HR), mean arterial pressure (MAP), aortic flow (AF), cardiac output index (COI), stroke volume index (SVI) and systemic vascular resistance (SVR) in rats with left coronary ligation (CAL) and in sham-operated rats (Sham) at the 6th a week after the operation addition, the degradation of rat BNP due to NEP has been the reduction in these plasma concentrations. Moreover, plasma concentrations of these peptides are sensitive shown to be less than that of rat ANP [10, 22] . Such indices for the severity of heart failure as described above pharmacokinetic differences may contribute to the lack of [21] . Therefore, we consider the reduction in the plasma ONO-9902-induced NEP inhibition leading to an increase ANP and BNP concentrations following chronic treatment in plasma BNP.
with ONO-9902 to be as a result of the improvement of the pathophysiology of CHF.
Long-term treatment with ONO-9902
The mechanism by which chronic treatment with ONO-9902 improved hemodynamic parameters of rats with CHF The major finding in the present study was that longshould be addressed. Since HR, cardiac contractility term treatment with ONO-9902 appreciably attenuated the (LVSP and 6dP/dt max), and myocardial hypertrophy CHF-induced increases in LVEDP and lung / body weight.
(heart weight) were not affected by ONO-9902 treatment, Furthermore, ONO-9902 treatment suppressed the CHFthe direct action of NEP inhibitor on the heart is unlikely. induced increase in SVR and decrease in COI. These Although ONO-9902 had no effect on MAP, it reduced results suggest that chronic treatment with this NEP LVEDP and SVR and increased COI. This implies that inhibitor may prevent the CHF-induced increases in both there may be vasodilation in both arterial and venous left ventricular pre-and after-load. Since this drug did not systems as similar to the consequence elicited by adminisaffect MAP, the reduction in SVR may secondarily imtration of a low dose of sodium nitroprusside [24] . Thus, prove COI in rats with CAL. To our knowledge, there are the results suggest that chronic inhibition of NEP may very few reports showing that long-term treatment with a improve pre-and after-load. A recent report demonstrated NEP inhibitor improved cardiac function. Yoshida et al. that 48-h infusion of ANP in patients with heart failure [23] reported that long-term treatment with the NEP declined the mean pulmonary capillary wedge pressure and inhibitor candoxatril had no effect on the cardiac contrac-SVR secondary to diuresis and vasodilation [25] . This tile function and plasma ANP level, though the renal NEP finding is consistent with the results in the present study. activity was inhibited by the treatment. We cannot explain
In addition to ANP and BNP, ET-1, a potent vasoconthe reason for the difference in these observations. One strictor peptide, also serves as a substrate for NEP. Indeed, possibility is that the dose of candoxatril (10 mg / kg / day) acute treatment with the NEP inhibitor candoxatril inmay have been so low that the plasma ANP level could not creased the circulating plasma level of ET-1 in patients reach the therapeutically effective levels in their model. with heart failure [26] . Thus, it is possible to consider that We found that the increases in plasma concentrations of long-term treatment with ONO-9902 increases the plasma ANP and BNP and LV content of ANP in rats with CAL ET-1 concentration and causes the detrimental effect in the were attenuated by chronic treatment with ONO-9902.
setting of CHF. However, chronic treatment with ONOSince ONO-9902 prevents the metabolic degradation of 9902 prevented the CHF-induced elevation of plasma and ANP and BNP, this fact seems to be discrepant with the LV ET-1 levels. Thus, it is unlikely that chronic NEP enzymatic inhibitory action of ONO-9902. One explanainhibition elevates plasma ET-1 level and worsens the tion for this apparent contradiction is that long-term severity of heart failure. treatment with ONO-9902 might lead to desensitize NEP
In conclusion, long-term NEP inhibition by ONO-9902 of the rat with CAL, resulting in an alteration of the exerted beneficial effects on hemodynamic and humoral inhibitory action of this drug on NEP. It has been reported factors probably by increasing the plasma concentration of that in rats with heart failure produced by AV fistula, ANP during the early period of administration to rats with long-term treatment with ecadotril elevated the plasma CHF. This drug may offer a new and effective therapeutic ANP concentration and improved the diminished renal approach to CHF. function [19] . The latter finding suggests that an increase in the plasma concentration of ANP is a prerequisite for long-lasting improvement of hemodynamic function by
